GlassScriptPhysician profile
Madhu Jodhani
NPI 1568419588
$7,815.35
in general payments reported to CMS, 2019-2025
34 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $251 · 2021: $572 · 2022: $1,551 · 2023: $782 · 2024: $3,076 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,120 · Food and Beverage: $1,941 · Education: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,120.00 |
| Food and Beverage | $1,941.18 |
| Education | $643.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,711.20 | 2019-2025 | Calquence, Farxiga, Airsupra |
| Abbvie INC. | $938.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $810.00 | 2022 | |
| Janssen Biotech, INC. | $745.87 | 2019-2025 | Erleada, Akeega, Balversa |
| Incyte Corporation | $296.58 | 2020-2025 | Jakafi |
| Pfizer INC. | $291.57 | 2019-2025 | |
| Lilly USA, LLC | $210.07 | 2024-2025 | Mounjaro, Jardiance, Kisunla |
| Astellas Pharma US INC | $208.13 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.97 | 2022-2025 | Iclusig, Vonvendi, Ninlaro |
| Intuitive Surgical, INC. | $144.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $126.42 | 2019-2023 | |
| Agios Pharmaceuticals, INC. | $100.75 | 2025 | Pyrukynd |
| Seagen INC. | $92.99 | 2025 | |
| Genentech USA, INC. | $88.49 | 2019 | |
| Celgene Corporation | $78.43 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $76.08 | 2024-2025 | Besremi |
| Asd Specialty Healthcare, LLC | $72.50 | 2019 | |
| Merck Sharp & Dohme LLC | $70.73 | 2019-2025 | Keytruda, Keytruda Qlex |
| Pharmacosmos Therapeutics INC. | $69.14 | 2024 | Monoferric |
| Glaxosmithkline, LLC. | $56.43 | 2020-2025 | Ojjaara, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $48.09 | 2023-2025 | |
| Dova Pharmaceuticals | $44.48 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $44.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.35 | 2019-2020 | |
| Taiho Oncology, INC. | $31.72 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $29.41 | 2019 | |
| Iovance Biotherapeutics, INC. | $28.39 | 2025 | Amtagvi |
| Geron Corporation | $27.75 | 2025 | Rytelo |
| Eisai INC. | $26.61 | 2024 | |
| Sobi, INC | $26.46 | 2023 | |
| Daiichi Sankyo INC. | $24.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.75 | 2025 | Voquezna |
| Allergan, INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhu Jodhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.